Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Endometrial Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 37Paclitaxel 18Cisplatin 18Carboplatin 14Nivolumab 13Hyperthermic Intraperitoneal Chemotherapy 13Docetaxel 11Cyclophosphamide 11Oxaliplatin 9Irinotecan 9Fluorouracil 9atezolizumab 8Trastuzumab 8Leucovorin 8Bevacizumab 8fludarabine 7Magnetic Resonance Spectroscopy 7Specimen Handling 6Ipilimumab 6Gemcitabine 6Mitomycin 5Cytoreduction Surgical Procedures 5Capecitabine 5durvalumab 4cemiplimab 4aldesleukin 4Taxes 4Psychiatric Rehabilitation 4Platinum 4Drug Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × pemigatinib × Gynecologic × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡